Pfizer Could Year-End Target Hit on 2-to-1 Trial Payoff
Pfizer stock climbs as analysts weigh a pivotal prostate cancer trial. A Guggenheim bull case sees a $36 target by ye...
We describe how low index readings can signal weakening momentum, possible capitulation, or upcoming reversals, with practical interpretation tips.
21,854 articlesPfizer stock climbs as analysts weigh a pivotal prostate cancer trial. A Guggenheim bull case sees a $36 target by ye...
Florida’s housing to-do list in 2026 features divergent markets, tighter loan conditions, and price concessions as bu...
Apple sits around $284 as traders weigh the next move. A robust quarter and expanding Services set the stage for a bu...
Visa and Mastercard lead the global payments world, forming a true duopoly. This article breaks down which stock off...
NVIDIA breached a $5.5 trillion market cap, marking a historic leap for a chipmaker tied to AI. The move highlights t...
A veteran lender outlines the three biggest traps in reverse mortgages as market conditions shift and seniors hold si...
Microsoft sits at a pivotal price near $420 as quarterly results underscore AI momentum and capex intensity. This rep...
The Cleveland Fed reports the five-year inflation outlook hasn’t been this high in 19 years, adding a new twist for i...
Bitcoin moved back toward the $80,000 mark as global markets priced in a potential de-escalation in Middle East tensi...
A high-profile courtroom moment becomes a real-world lesson in protecting your finances. Learn how to safeguard asset...
New data from Goldman Sachs shows AI-driven job losses remain concentrated in early-career roles, with Gen Z bearing ...
XRP slid over the past week as the Senate advances the CLARITY Act toward a floor vote, renewing questions about regu...